Purchase Order VA580W13802
- Not listed
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company, for the provision of the Provant Therapy System and related rental services. The contract has a ceiling value of $7,142.85 and was awarded on February 18, 2011, with a completion date of March 18, 2011. The Provant Therapy System is a patented, noninvasive regenerative medicine product indicated for the palliative treatment of...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a for-profit medical technology company. The $4,820.98 contract is for the Provant Therapy System, a patented non-invasive regenerative medicine product indicated for post-operative pain and edema treatment. The contract was awarded under Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A contract for medical equipment and...
- This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 contract is for the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical. The Provant Therapy System is indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of March 16, 2011. Regenesis...
- This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The contract is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has a ceiling value of $7,231.47 and was awarded on May 24, 2011, with a completion date of June 24, 2011....
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc. for the Provant Therapy System, a non-invasive regenerative medicine product. The contract has a ceiling value of $3,675.14 and a completion date of August 12, 2011. Regenesis Biomedical is the prime contractor and manufacturer of the Provant Therapy System, which is indicated for the palliative treatment of post-operative pain and edema. The contract was awarded...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company, for the Provant Therapy System. The contract, valued at $4,992.40, is for the provision of the Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is not associated with a set-aside program and appears to be part of Regenesis...
- This is a $3,645.14 firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc. for the Provant Therapy System, a noninvasive regenerative medicine product. The contract is not set-aside and was awarded under Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies. The Provant Therapy System is indicated for palliative treatment of post-operative pain and edema, and Regenesis Biomedical appears to be the...
- This is a $4,882.79 firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a for-profit medical device manufacturer. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract was awarded on December 14, 2010, with a completion date of January 14, 2011. No set-aside was...
- This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has a ceiling value of $7,231.47 and a completion date of June 24, 2011. There is no set-aside designation...
- This federal contract award is for the purchase of the Provant Therapy System from Regenesis Biomedical Inc., a medical technology company. The $4,820.98 firm fixed-price purchase order was awarded by the U.S. Department of Veterans Affairs (VA) on December 28, 2010, with an ultimate completion date of January 28, 2011. The contract was awarded against Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies, and did not utilize any set-aside designations....
This is a purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a for-profit medical technology company, for the provision of the Provant Therapy System. The Provant Therapy System is a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has a ceiling value of $4,882.79 and is a firm fixed-price arrangement. It was awarded on January 27, 2011, with a planned completion date of February 27, 2011. The contract was not set aside for any preferential contracting vehicle. Based on the information provided, Regenesis Biomedical Inc. appears to be the prime contractor and does not utilize any major subcontractors. This contract is likely part of Regenesis Biomedical's broader GSA Schedule 65-II-A contract with the VA for medical equipment and supplies, through which the company provides its proprietary Provant Therapy System to VA healthcare facilities across different regions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 1/27/11 |